Novel delivery strategies for glioblastoma

Cancer Journal

Volumn 18, Issue 1, 2012, Pages 89-99

  Zhou, Jiangbing ^a   Atsina, Kofi Buaku ^a   Himes, Benjamin T ^a   Strohbehn, Garth W ^a   Saltzman, W Mark ^a  

^a Yale University   (United States)

Author keywords

brain cancer stem cells; convection based delivery; Drug delivery; gene therapy; nanocarriers

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CAMPTOTHECIN; CARBOPLATIN; CARMUSTINE; CD133 ANTIGEN; CETUXIMAB; CISPLATIN; DEPSIPEPTIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; IRON OXIDE; LAPATINIB; LIPOSOME; METHOTREXATE; NIMOTUZUMAB; PACLITAXEL; PANOBINOSTAT; PAZOPANIB; PERIFOSINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLYGLACTIN; SORAFENIB; SURAMIN; TEMOZOLOMIDE; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT; XL 765;

BLOOD BRAIN BARRIER; CELL PROLIFERATION; CELL SURVIVAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SAFETY; GLIOBLASTOMA; PRIORITY JOURNAL; REVIEW; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; HUMANS; NANOSTRUCTURES; NEOPLASTIC STEM CELLS;

EID: 84863059930     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318244d8ae     Document Type: Review

References (212)

1. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93-108. (Pubitemid 40287792)
2. Fisher PG, Buffler PA. Malignant gliomas in 2005: where to GO from here? JAMA. 2005;293:615-617. (Pubitemid 40171245)
3. Scott CB, Scarantino C, Urtasun R, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive part-itioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int JRadiat Oncol Biol Phys. 1998;40:51-55 (Pubitemid 28027566)
4. National Brain Tumor Society. Available at: www.braintumor.org/ get-involved/advocacy-public-policy/know-the-issues.html. Accessed October 28, 2011.
5. Sathornsumetee S, Rich JN. New treatment strategies for malignant gliomas. Expert Rev Anticancer. 2006;6:1087-1104. (Pubitemid 44203386)
6. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine im-plant. Clin Pharmacokinet. 2002;41:403-419.
7. Sawyer AJ, Piepmeier JM, Saltzman WM. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J Biol Med. 2007;79:141-152.
8. Yang M, Tamargo R, Brem H. Controlled delivery of 1,3-bis(2-chloroethyl)- 1-nitrosourea from ethylene-vinyl acetate copolymer. Cancer Res. 1989; 49:5103-5107. (Pubitemid 19239352)
9. Tamargo RJ, Myseros JS, Epstein JI, et al. Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res. 1993;53:329-333. (Pubitemid 23031845)
10. Fung LK, Ewend MG, Sills A, et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and pac-litaxel from a biodegradable polymer implant in the monkey brain. Cancer Res. 1998;58:672-684. (Pubitemid 28099477)
11. Fung L, Shin M, Tyler B, et al. Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm Res. 1996;13:671-682. (Pubitemid 26156217)
12. Brem H, Mahaley M, Vick N, et al. Interstitial chemotherapy with drug polymer implants for the treatment ofrecurrent gliomas. J Neurosurg. 1991;74:441-446.
13. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegrad-able polymers ofchemotherapy for recurrent gliomas. Lancet. 1995; 345:1008-1012.
14. Dang WB, Colvin OM, Brem H, et al. Covalent coupling ofmetho-trexate to dextran enhances the penetration ofcytotoxicity into a tissue-likematrix. Cancer Res. 1994;54:1729-1735. (Pubitemid 24116177)
15. Walter KA, Cahan MA, Gur A, et al. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res. 1994;54:2207-2212. (Pubitemid 24138696)
16. Reinhard C, Radomsky ML, Saltzman WM, et al. Polymeric controlled release of dexamethasone in normal rat brain. J Control Release. 1991;16:331-340.
17. Fleming AB, Haverstick K, Saltzman WM. In vitro cytotoxicity and in vivo distribution after direct delivery of PEG-camptothecin conjugates to the rat brain. Bioconjug Chem. 2004;15:1364-1375. (Pubitemid 39552027)
18. Allard E, Passirani C, Benoit JP Convection-enhanced delivery ofnano-carriers for the treatment of brain tumors. Biomaterials. 2009;30: 2302-2318.
19. Raghavan R, Brady ML, Rodriguez-Ponce MI, et al. Convection-enhanced delivery of therapeutics for brain disease, and its optimiza-tion. Neurosurg Focus. 2006;20:E12.
20. Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain.Proc Natl Acad Sci USA. 1994;91: 2076-2080. (Pubitemid 24092045)
21. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role ofinterstitial pressure and convection. Microvasc Res. 1989;37:77-104. (Pubitemid 19045527)
22. Smith JH, Humphrey JA. Interstitial transport and transvascular fluid exchange during infusion into brain and tumor tissue. Microvasc Res. 2007;73:58-73. (Pubitemid 46072892)
23. Sampson JH, Archer G, Pedain C, et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. Clinical article. J Neurosurg. 2010;113:301-309.
24. Bennewitz M, Saltzman WM. Nanotechnology for delivery ofdrugs to the brain for epilepsy. Neurotherapeutics. 2009;6:323-336.
25. Fahmy TM, Fong PM, Goyal A, et al. Targeted nanoparticles for drug delivery. Nano Today. 2005;8:18-26.
26. Lockman PR, Oyewumi MO, Koziara JM, et al. Brain uptake of thiamine-coatednanoparticles. JControl Release. 2003;93:271-282.
27. Koziara J, Lockman PR, Allen DD, et al. In situ blood-brain barrier transport of nanoparticles. Pharm Res. 2003;20:1772-1778. (Pubitemid 37449450)
28. Kreuter J, Ramge P, Petrov V, et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles delivery drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res. 2003;20:409-416. (Pubitemid 36288370)
29. Kircher MF, Mahmood U, King RS, et al. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res. 2003;63:8122-8125. (Pubitemid 37549457)
30. Saito R, Bringas JR, Mc Knight TR, et al. Distribution ofliposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res. 2004;64: 2572-2579. (Pubitemid 38523915)
31. Yamashita Y, Krauze MT, Kawaguchi T, et al. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in in-tracranial brain tumorxenografts. Neuro-oncol. 2007;9:20-28. (Pubitemid 46543485)
32. Krauze MT, Noble CO, Kawaguchi T, et al. Convection-enhanced de-livery ofnanoliposomal CPT-11 (irinotecan) and PEGylated liposo-mal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro-oncol. 2007;9:393-403.
33. Miyata S, Kawabata S, Hiramatsu R, et al. Computed tomography imaging of transferrin targeting liposomes encapsulating both boron and iodine contrast agents by convection-enhanced delivery to F98 rat glioma for boron neutron capture therapy. Neurosurgery. 2011;68: 1380-1387; discussion 1387.
34. Dickinson PJ, Le Couteur RA, Higgins RJ, et al. Canine spontaneous glioma: a translational model system for convection-enhanced delivery. Neuro-oncol. 2010;12:928-940.
35. Saito R, Krauze MT, Bringas JR, et al. Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging ofconvection-enhanced delivery in the primate brain. Exp Neurol. 2005;196:381-389. (Pubitemid 41607827)
36. Krauze MT, Mc Knight TR, Yamashita Y, et al. Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Protoc. 2005;16:20-26. (Pubitemid 41774067)
37. Saito R, Krauze MT, Noble CO, et al. Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery. J Neurosci Methods. 2006;154:225-232. (Pubitemid 43949058)
38. Krauze MT, Forsayeth J, Yin D, et al. Convection-enhanced delivery of liposomes to primate brain. Method Enzymol. 2009;465:349-362.
39. Voges J, Reszka R, Gossmann A, et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol. 2003; 54:479-487. (Pubitemid 37176543)
40. Ren H, Boulikas T, Lundstrom K, et al. Immunogene therapy ofrecurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene-a phase I/II clinical protocol. J Neurooncol. 2003;64:147-154. (Pubitemid 36992469)
41. Sawyer AJ, Saucier-Sawyer JK, Booth CJ, et al. Convection-enhanced delivery ofcamptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Drug Deliv Transl Res. 2011;1:34-42.
42. Neeves KB, Sawyer AJ, Foley CP, et al. Dilation and degradation of the brain extracellular matrix enhances penetration ofinfused polymer nanoparticles. Brain Res. 2007;1180:121-132. (Pubitemid 350018737)
43. Thorne RG, Nicholson C. Invivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space. Proc Natl Acad Sci USA. 2006;103:5567-5572.
44. Hobbs SK, Monsky WL, Yuan F, et al. Regulation oftransport path-ways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA. 1998;95:4607-4612. (Pubitemid 28207960)
45. Patel T, Zhou J, Piepmeier JM, et al. Ultrasmall polymeric nanoparti-cles improve distribution volume during convection-enhanced delivery (abstract). Neuro-oncol. 2010;12:91.
46. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concom-itant and adjuvant temozolomide for glioblastoma. New Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
47. Adamson C, Kanu OO, Mehta AI, et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs. 2009;18:1061-1083.
48. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000;6:2585-2597. (Pubitemid 30482092)
49. Marupudi NI, Han JE, Li KW, et al. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf. 2007; 6:609-621. (Pubitemid 351308218)
50. Sunayama J, Sato A, Matsuda K, et al. Dual blocking of m Tor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro-oncol. 2010;12:1205-1219.
51. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLo SMed. 2008;5:e8.
52. Metcalf CA, Bohacek R, Rozamus LW, et al. Structure-based design of AP23573, a phosphorous-containing analog of rapamycin for anti-tumor therapy. Proc Am Assoc Cancer Res. 2004;45:2476.
53. Mita M, Sankhala K, Abdel-Karim I, et al. Deforolimus (AP23573) a novel m TOR inhibitor in clinical development. Expert Opin Inv Drug. 2008;17:1947-1954.
54. Reardon DA, Quinn JA, Vredenburgh JJ, et al. Phase 1 trial ofgefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res. 2006;12:860-868. (Pubitemid 43259869)
55. Falcon BL, Barr S, Gokhale PC, et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor prop-erties ofdual m TORC1/m TORC2 inhibitors. Cancer Res. 2011;71: 1573-1583.
56. Prasad G, Sottero T, Yang X, et al. Inhibition of PI3K/m TOR pathways in glioblastoma and implications for combination therapy with temo-zolomide. Neuro-oncol. 2011;13:384-392.
57. Maira SM, Stauffer F, Brueggen J, et al. Identification and characteriza-tion of NVPBEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008;7:1851-1863.
58. Schultz RM, Merriman RL, Andis SL, et al. In vitro and in vivo antitu-mor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res. 1995;15:1135-1139.
59. Yang F, Brown C, Buettner R, et al. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation ofsignal transducers and activators of transcription 3. Mol Cancer Ther. 2010;9:953-962.
60. Siegelin MD, Raskett CM, Gilbert CA, et al. Sorafenib exerts anti-glioma activity in vitro and in vivo. Neurosci Lett. 2010;478: 165-170.
61. Wick W, Weller M, Weiler M, et al. Pathway inhibition: emerging mo-leculartargets fortreating glioblastoma. Neuro-oncol. 2011; 13: 566-579.
62. Yung WK, Vredenburgh JJ, Cloughesy TF, et al. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study Neuro-oncol. 2010;12:1061-1070.
63. Wang MY, Lu KV, Zhu S, et al. Mammalian target of rapamycin in-hibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 2006;66:7864-7869. (Pubitemid 44299148)
64. Diaz Miqueli A, Rolff J, Lemm M, et al. Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Brit JCancer. 2009;100:950-958.
65. Franceschi E, Cavallo G, Lonardi S, et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Brit J Cancer. 2007;96:1047-1051. (Pubitemid 46608313)
66. Pfeffer MR, Levitt ML, Aderka D. Gefitinib in recurrent glioblastoma. J Clin Oncol. 2004;22:2755-2756; authorreply 2756.
67. Hegi ME, Diserens AC, Bady P, et al. Pathway analysis of glioblas-toma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib-a phase II trial. Mol Cancer Ther. 2011;10: 1102-1112.
68. Goudar RK, Shi Q, Hjelmeland MD, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target ofrap-amycin (RAD001) offers improved glioblastoma tumor growth inhi-bition. Mol Cancer Ther. 2005;4:101-112. (Pubitemid 40268071)
69. Eller JL, Longo SL, Kyle MM, et al. Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery. 2005; 56:155-162; discussion 162. (Pubitemid 40054001)
70. Thiessen B, Stewart C, Tsao M, et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, phar-macokinetics and molecular correlation. Cancer Chemother Pharmacol. 2010;65:353-361.
71. Guo D, Prins RM, Dang J, et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblas-tomas to antilipogenic therapy. Sci Signal. 2009;2:ra82.
72. Strawn LM, Kabbinavar F, Schwartz DP, et al. Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumorxenografts. Clin Cancer Res. 2000;6:2931-2940. (Pubitemid 30482136)
73. Grossman SA, Phuphanich S, Lesser G, et al. Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. JClin Oncol. 2001;19:3260-3266. (Pubitemid 32591444)
74. Laterra JJ, Grossman SA, Carson KA, et al. Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. Neuro-oncol. 2004;6:15-20. (Pubitemid 38139634)
75. Glass TL, Liu TJ, Yung WK. Inhibition ofcell growth in human glioblas-toma cell lines by farnesyltransferase inhibitor SCH66336. Neuro-oncol. 2000;2:151-158.
76. Chaponis D, Barnes JW, Dellagatta JL, et al. Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. J Neurooncol. 2011;104:179-189.
77. Cloughesy TF, Wen PY, Robins HI, et al. Phase II trial oftipifarnib in patients with recurrent malignant glioma either receiving or not receiv-ing enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2006;24:3651-3656. (Pubitemid 46630540)
78. Lustig R, Mikkelsen T, Lesser G, et al. Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. Neuro-oncol. 2008;10:1004-1009.
79. Moyal EC, Laprie A, Delannes M, et al. Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme. Int JRadiat Oncol Biol Phys. 2007;68:1396-1401. (Pubitemid 47176810)
80. Sarcar B, Kahali S, Chinnaiyan P. Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines. J Neurooncol. 2010;99:201-207.
81. Galanis E, Jaeckle KA, Maurer MJ, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol. 2009;27:2052-2058.
82. Sawa H, Murakami H, Kumagai M, et al. Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathol. 2004;107: 523-531. (Pubitemid 38765394)
83. Zhu H, Woolfenden S, Bronson RT, et al. The novel Hsp90 inhibi-tor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme. Mol Cancer Ther. 2010;9: 2618-2626.
84. Régina A, Demeule M, Ché C, et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector angiopep-2. Brit J Pharmacol. 2008;155:185-197.
85. Thomas FC, Taskar K, Rudraraju V, etal. Uptakeof ANG1005, anovel paclitaxel derivative, through the blood-brain barrier into brain and ex-perimental brain metastases ofbreast cancer. Pharm Res. 2009;26: 2486-2494.
86. De Groot JF, Prados M, Urqhart T, et al. A phase II study of XL184 in patients with progressive glioblastoma multiforme (GBM) in first or second relapse. J Clin Oncol. 2009;27:2047.
87. Wen PY, Prados M, Schiff D, et al. Phase 2 study of XL184 (BMS-907351), an inhibitor of MET, VEGFR2, and RET in patients with progressive glioblastoma. J Clin Oncol. 2010;28:15s.
88. Price A, Shi Q, Morris D, et al. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metallo- proteinaseinhibitor AG3340. Clin Cancer Res. 1999;5:845-854. (Pubitemid 29180837)
89. Levine PA, Phuphanich S, Glantz MJ, et al. Randomized phase II study of temozolomide (TMZ) with and without the metalloprotease (MMP) inhibitor prinomastat in patients with glioblastoma multiforme (GBM) following best surgery and radiation therapy. Proc Annu Meet Am Soc Clin Oncol. 2002;21:100.
90. Milano V, Piao Y, La Fortune T, et al. Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Mol Cancer Ther. 2009;8:394-406.
91. Lu-Emerson C, Norden AD, Drappatz J, et al. Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. J Neurooncol. 2010;104:287-291.
92. Iwamoto FM, Lamborn KR, Robins HI, et al. Phase II trial ofpazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro-oncol. 2010;12:855-861.
93. Razis E, Selviaridis P, Labropoulos S, et al. Phase II study ofneo-adjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin Cancer Res. 2009;15:6258-6266.
94. Dresemann G. Imatinib and hydroxyurea in pretreated progressive glio-blastomamultiforme: a patientseries. Ann Oncol. 2005;16:1702-1708. (Pubitemid 41510147)
95. Butowski N, Chang SM, Lamborn KR, et al. Enzastaurin plus temoz-olomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro-oncol. 2010;12:608-613.
96. Kreisl TN, Kim L, Moore K, et al. A phase I trial of enzastaurin in patientswithrecurrentgliomas. Clin Cancer Res. 2009;15:3617-3623.
97. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent in-tracranial glioblastoma. J Clin Oncol. 2010;28:1168-1174.
98. Unterkircher T, Cristofanon S, Vellanki SH, et al. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by in-creasing t Bid stability and mitochondrial apoptosis. Clin Cancer Res. 2011;17:4019-4030.
99. Balyasnikova IV, Ferguson SD, Han Y, et al. Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with gli-omaxenografts. Cancer Lett. 2011;310:148-159.
100. Pedeboscq S, L'Azou B, Passagne I, et al. Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. JExp Ther Oncol. 2008;7:99-111.
101. Kardosh A, Golden EB, Pyrko P, et al. Aggravated endoplasmic re-ticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Cancer Res. 2008;68:843-851. (Pubitemid 351206762)
102. Phuphanich S, Supko JG, Carson KA, et al. Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol. 2010;100:95-103.
103. Visnyei K, Onodera H, Damoiseaux R, et al. A molecular screening approach to identify and characterize inhibitors of glioblastoma mul-tiforme stem cells. Mol Cancer Ther. 2011;10:1818-1828.
104. Gerstner ER, Eichler AF, Plotkin SR, et al. Phase I trial with biomarker studies ofvatalanib (PTK787) in patients with newly diagnosed glio-blastoma treated with enzyme inducing anti-epileptic drugs and stan-dard radiation and temozolomide. J Neurooncol. 2011;103:325-332.
105. Morabito A, De Maio E, Di Maio M, et al. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist. 2006;11:753-764. (Pubitemid 44157563)
106. Homsi J, Daud AI. Spectrum ofactivity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control. 2007;14:285-294. (Pubitemid 47057799)
107. Michaud K, Solomon DA, Oermann E, et al. Pharmacologic inhibition of cdk4/6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 2010;70:3228-3238.
108. Wiedemeyer WR, Dunn IF, Quayle SN, et al. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci U S A. 2010;107:11501-11506.
109. Pore N, Gupta AK, Cerniglia GJ, et al. HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells. Neoplasia (New York, NY). 2006;8:889-895.
110. Tian X,Ye J,Alonso-Basanta M, etal. Modulationof CCAAT/enhancer binding protein homologous protein (CHOP)-dependent DR5 expres-sion by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). JBiol Chem. 2011;286:29408-29416.
111. Pyrko P, Kardosh A, Wang W, et al. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplas-mic reticulum stress. Cancer Res. 2007;67:10920-10928. (Pubitemid 350145921)
112. Guzman M, Sanchez C, Galve-Roperh I. Control of the cell survival/ death decision by cannabinoids. JMol Med (Berl). 2001;78:613-625.
113. Galve-Roperh I, Sanchez C, Cortes ML, et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med. 2000;6: 313-319. (Pubitemid 30148624)
114. Sanchez C, Galve-Roperh I, Canova C, et al. Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBSLett. 1998;436:6-10. (Pubitemid 28454597)
115. Hu SS, Bradshaw HB, Benton VM, et al. The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine. Prostaglandins Leukot Essent Fatty Acids. 2009;81:291-301.
116. Davies JW, Hainsworth AH, Guerin CJ, et al. Pharmacology ofcap-saicin-, anandamide-, and N-arachidonoyl-dopamine-evokedcell death in a homogeneous transient receptor potential vanilloid subtype 1 re-ceptor population. Brit JAnaesth. 2010;104:596-602.
117. Chu CJ, Huang SM, De Petrocellis L, et al. N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. JBiol Chem. 2003;278:13633-13639. (Pubitemid 36799898)
118. Xia S, Li Y, Rosen EM, et al. Ribotoxic stress sensitizes glioblastoma cells to death receptor induced apoptosis: requirements for c-Jun NH2-terminal kinase and Bim. Mol Cancer Res. 2007;5:783-792. (Pubitemid 47294806)
119. Chau N-M, Rogers P, Aherne W, et al. Identification ofnovel small molecule inhibitors ofhypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1 alpha induction in response to hypoxic stress and growth factors. Cancer Res. 2005;65:4918-4928. (Pubitemid 40740832)
120. Kong H, Lee S, Beebe K, et al. Emetine promotes von Hippel-Lindau- independent degradation ofhypoxia-inducible factor-2 in clear cell renal carcinoma. Mol Pharmacol. 2010;78:1072-1078.
121. Takamiya Y, Brem H, Ojeifo J, et al. AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery. 1994; 34:869-875; discussion 875. (Pubitemid 24130067)
122. Bar EE, Chaudhry A, Lin A, et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells. 2007;25:2524-2533. (Pubitemid 47582744)
123. Jones RJ, Matsui WH, Smith BD. Cancer stem cells: are we missing the target? J Natl Cancer Inst. 2004;96:583-585. (Pubitemid 38584981)
124. Clarke MF Neurobiology: at the root of brain cancer. Nature. 2004; 432:281-282.
125. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821-5828. (Pubitemid 37187480)
126. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stemlike neural precursors from human glioblastoma. Cancer Res. 2004;64:7011-7021. (Pubitemid 39331011)
127. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401. (Pubitemid 39551674)
128. Yuan X, Curtin J, Xiong Y, et al. Isolation ofcancer stem cells from adult glioblastoma multiforme. Oncogene. 2004;23:9392-9400. (Pubitemid 40069671)
129. Bao S, Wu Q, Mc Lendon RE, et al. Glioma stem cells promote ra-dioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756-760. (Pubitemid 44949604)
130. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth fac-tor. Cancer Res. 2006;66:7843-7848. (Pubitemid 44299144)
131. Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth char-acteristics andmolecularprofiles. Cancer Res. 2007;67:4010-4015. (Pubitemid 46815044)
132. Gunther HS, Schmidt NO, Phillips HS, et al. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to mo-lecular and phenotypic criteria. Oncogene. 2007;27:2897-2909. (Pubitemid 351620450)
133. Fan X, Salford LG, Widegren B. Glioma stem cells: evidence and limitation. Semin Cancer Biol. 2007;17:214-218. (Pubitemid 46413075)
134. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11:69-82. (Pubitemid 46054518)
135. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-111. (Pubitemid 33041634)
136. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275-284. (Pubitemid 40488633)
137. Tang C, Chua CL, Ang BT. Insights into the cancer stem cell model of glioma tumorigenesis. Ann Acad Med Singapore. 2007;36:352-357. (Pubitemid 47121450)
138. Liu G, Yuan X, Zeng Z, et al. Analysis ofgene expression and che-moresistance of CD133+cancerstemcells in glioblastoma. Mol Cancer. 2006;5:67.
139. Eramo A, Ricci-Vitiani L, Zeuner A, et al. Chemotherapy resistance of glioblastomastemcells. Cell Death Differ. 2006;13:1238-1241.
140. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct ''side pop-ulation'' of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 2004;101:14228-14233. (Pubitemid 39305058)
141. Abbott A. Cancer: the root of the problem. Nature. 2006;442:742-743.
142. Bleau AM, Hambardzumyan D, Ozawa T, et al. PTEN/PI3K/Akt path-way regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 2009;4:226-235.
143. Gallia GL, Tyler BM, Hann CL, et al. Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol Cancer Ther. 2009;8:386-393.
144. Fan X, Matsui W, Khaki L, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006;66:7445-7452. (Pubitemid 44289197)
145. Fan X, Khaki L, Zhu TS, et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neu-rospheres andxenografts. Stem Cells. 2010;28:5-16.
146. Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006;444:761-765. (Pubitemid 44949605)
147. Soeda A, Inagaki A, Oka N, et al. Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells. JBiol Chem. 2008;283:10958-10966.
148. Ikushima H, Todo T, Ino Y, et al. Autocrine TGF-beta signaling main-tains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell. 2009;5:504-514.
149. Li Z, Bao S, Wu Q, et al. Hypoxia-inducible factors regulate tumori-genic capacity of glioma stem cells. Cancer Cell. 2009;15:501-513.
150. Wurdak H, Zhu S, Romero A, et al. An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation. Cell Stem Cell. 2010;6:37-47.
151. Miller CR, Williams CR, Buchsbaum DJ, et al. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is ef-fective for experimental human glioblastomas. Cancer Res. 2002;62: 773-780. (Pubitemid 34126953)
152. Chambers R, Gillespie GY, Soroceanu L, et al. Comparison ofgenet-ically engineered herpes simplex viruses for the treatment of brain tumors in a SCID mouse model of human malignant glioma. Proc Natl Acad Sci USA. 1995;92:1411-1415.
153. Hamel W, Zirkel D, Mehdorn HM, et al. (E)-5-(2-bromovinyl)-2-deoxyuridine potentiates ganciclovir-mediated cytotoxicity on herpes simplexvirus- thymidinekinase-expressingcells. Cancer Gene Therapy. 2001;8:388-396. (Pubitemid 32685646)
154. Rainov NG. A phase III clinical evaluation ofherpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther. 2000;11:2389-2401.
155. Zhang W, Fine H. Mechanisms of Gliomagenesis. In: Janigro O, eds. The Cell Cycle in the Central Nervous System. Totowa, NJ: Humana Press. 2006;VI:449-462.
156. Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA. 1998;95:15406-15411. (Pubitemid 29018711)
157. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastomamultiforme. Science. 2008;321:1807-1812.
158. Symonds H, Krall L, Remington L, et al. p53-Dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 1994;78: 703-711.
159. Schmidt EE, Ichimura K, Reifenberger G, et al. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority ofglio-blastomas. Cancer Res. 1994;54:6321-6324.
160. Rao SK, Edwards J, Joshi AD, et al. A survey of glioblastoma genomic amplifications and deletions. JNeurooncol. 2010;96:169-179.
161. Yan H, Parsons DW, Jin G, etal. IDH1 and IDH2mutations in gliomas. New Engl JMed. 2009;360:765-773.
162. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dom-inantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009;324:261-265.
163. Mathieu J, Zhang Z, Zhou W, et al. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res. 2011;71:4640-4652.
164. Ciafre SA, Galardi S, Mangiola A, et al. Extensive modulation of a set of micro RNAs in primary glioblastoma. Biochem Bioph Res Co. 2005; 334:1351-1358. (Pubitemid 41074723)
165. Kefas B, Godlewski J, Comeau L, et al. micro RNA-7 inhibits the epi-dermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008;68:3566-3572.
166. Chan JA, Krichevsky AM, Kosik KS. Micro RNA-21 is an anti-apoptotic factor in human glioblastoma cells. Cancer Res. 2005;65: 6029-6033. (Pubitemid 40994386)
167. Corsten MF, Miranda R, Kasmieh R, et al. Micro RNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res. 2007;67:8994-9000. (Pubitemid 47535880)
168. Gabriely G, Yi M, Narayan RS, et al. Human glioma growth is con-trolled by micro RNA-10b. Cancer Res. 2011;71:3563-3572.
169. Turner JD, Williamson R, Almefty KK, et al. The many roles of micro RNAs in brain tumor biology. Neurosurg Focus. 2010;28:E3.
170. Kim T-M, Huang W, Park R, et al. A developmental taxonomy of glioblastoma defined and maintained by Micro RNAs. Cancer Res. 2011; 71:3387-3399.
171. Vecil GG, Lang FF Clinical trials ofadenoviruses in brain tumors: a review of Adp53 and oncolytic adenoviruses. J Neurooncol. 2003;65: 237-246. (Pubitemid 37526816)
172. Chiu T-L, Lin S-Z, Hsieh W-H, et al. AAV2-mediated interleukin-12 in the treatment ofmalignant brain tumors through activation of NK cells. Int JOncol. 2009;35:1361-1367.
173. Harding TC, Lalani AS, Roberts BN, et al. AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma. Mol Ther. 2006;13:956-966.
174. Nilaver G, Muldoon LL, Kroll RA, et al. Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrierdisruption. Proc Natl Acad Sci USA. 1995;92:9829-9833.
175. Pulkkanen KJ, Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol Ther. 2005;12:585-598. (Pubitemid 41350140)
176. Templeton NS, Lasic DD, Frederik PM, et al. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol. 1997;15:647-652. (Pubitemid 27291165)
177. Chen Y, Bathula SR, Yang Q, et al. Targeted nanoparticles deliver si RNA to melanoma. JInvest Dermatol. 2010;130:2790-2798.
178. Kato T, Natsume A, Toda H, et al. Efficient delivery of liposome-mediated MGMTsi RNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Ther. 2010;17:1363-1371.
179. Gupta B, Levchenko TS, Torchilin VP. TAT peptide-modified lipo-somes provide enhanced gene delivery to intracranial human brain tumorxenografts in nude mice. Oncol Res. 2007;16:351-359. (Pubitemid 47413251)
180. Jacobs A, Voges J, Reszka R, et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet. 2001;358:727-729. (Pubitemid 32823405)
181. Han L, Zhang A, Wang H, et al. Tat-BMPs-PAMAM conjugates en-hance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo. Hum Gene Ther. 2010;21:417-426.
182. Huang R, Ke W, Han L, et al. Targeted delivery ofchlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration. Biomaterials. 2011;32:2399-2406.
183. Hwang DW, Son S, Jang J, etal.Abrain-targetedrabiesvirus glycoprotein-disulfide linked PEI nanocarrier for delivery ofneuro-genic micro RNA. Biomaterials. 2011;32:4968-4975.
184. Gao X, Yao L, Song Q, et al. The association of autophagy with polyethylenimine-induced cytotoxity in nephritic and hepatic cell lines. Biomaterials. 2011.
185. Kafil V, Omidi Y Cytotoxic impacts of linear and branched poly-ethylenimine nanostructures in A431 cells.Bio Impacts. 2011;1:23-30.
186. Tros de Ilarduya C, Sun Y, Duzgunes N. Gene delivery by lipoplexes and polyplexes. Eur JPharm Sci. 2010;40:159-170.
187. Lv H, Zhang S, Wang B, et al. Toxicity ofcationic lipids and cationic polymers in gene delivery. J Control Release. 2006;114:100-109. (Pubitemid 44128621)
188. Sunshine JC, Akanda MI, Li D, et al. Effects ofbase polymer hydro-phobicity and endgroup modification on polymeric gene delivery Biomacromolecules. 2011;12:3592-3600.
189. Liu J, Jiang Z, Zhou J, et al. Enzyme-synthesized poly(amine-co-esters) as nonviral vectors forgene delivery. JBiomed Mater Res A. 2011;96: 456-465.
190. Zhou J, Liu J, Jiang Z, et al. Biodegradable poly (amine-co-ester) ter-polymers for targeted gene delivery. Nat Mater. 2011;11:82-90.
191. Zhou J, Patel T, Fu M, et al. Octa-functional PLGA nanoparticles for targeted and efficient si RNA delivery to tumors. Biomaterials. 2012;33: 583-591.
192. Mardor Y, Roth Y, Lidar Z, et al. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res. 2001;61:4971-4973. (Pubitemid 32681520)
193. Lidar Z, Mardor Y, Jonas T, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg. 2004;100:472-479. (Pubitemid 38269075)
194. Vogelbaum MA. Convection enhanced delivery for the treatment of malignant gliomas: symposium review. JNeurooncol. 2005;73:57-69. (Pubitemid 40823269)
195. Sampson JH, Brady M, Raghavan R, et al. Colocalization ofgadolin-ium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. Neurosurgery. 2011;69:668-676.
196. Mardor Y, Rahav O, Zauberman Y, et al. Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring. Cancer Res. 2005;65:6858-6863. (Pubitemid 41065083)
197. Doiron AL, Chu K, Ali A, et al. Preparation and initial characterization ofbiodegradable particles containing gadolinium-DTPA contrast agent for enhanced MRI. Proc Natl Acad Sci US A. 2008;105:17232-17237.
198. Ratzinger G,Agrawal P, Korner W, etal. Surface modification of PLGA nanospheres with Gd-DTPA and Gd-DOTA for high-relaxivity MRI contrast agents. Biomaterials. 2010;31:8716-8723.
199. Bass LA, Wang M, Welch MJ, et al. In vivo transchelation ofcopper-64 from TETAoctreotide to superoxide dismutase in rat liver. Bioconjug Chem. 2000;11:527-532. (Pubitemid 30597722)
200. Hadjipanayis CG, Machaidze R, Kaluzova M, et al. EGFRv III antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res. 2010;70:6303-6312.
201. Sampson JH, Brady ML, Petry NA, et al. Intracerebral infusate distri-bution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects oftarget anatomy and catheter positioning. Neurosurgery. 2007;60:ONS89-ONS98; discussion ONS98-ONS99.
202. Merkel OM, Librizzi D, Pfestroff A, et al. In vivo SPECT and real-time gamma camera imaging of biodistribution and pharmacokinetics of si RNA delivery using an optimized radiolabeling and purification procedure. Bioconjug Chem. 2009;20:174-182.
203. Dye M.PET& SPECT:happytogether.Imaging Econ. 2005 [cited2011; available at: www.imagingeconomics.com/issues/articles/MI-2005-06-01.asp].
204. van der Have F, Vastenhouw B, Ramakers RM, et al. U-SPECT-II: an ultra-high-resolution device for molecular small-animal imaging. JNucl Med. 2009;50:599-605.
205. Qian J, Bradley EL, Majewski S, et al. A small-animal imaging sys-tem capable ofmultipinhole circular/helical SPECT and parallel-hole SPECT. Nucl Instrum Methods Phys Res A. 2008;594:102-110.
206. 18F] fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced de-livery ofpaclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2005;32:1018-1025. (Pubitemid 41339276)
207. Schluep T, Hwang J, Hildebrandt IJ, et al. Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci U S A. 2009;106: 11394-11399.
208. Sirianni R, Carson R, Zheng M, et al. Development ofd PET, a non-invasive imaging technique to measure the distribution of drugs after direct delivery to the brain. J Nucl Med. 2010;51:-829.
209. Pauleit D, Floeth F, Hamacher K, et al. O-(2-[ F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment ofcerebral gliomas. Brain. 2005;128:678-687. (Pubitemid 40380202)
210. Plotkin M, Gneveckow U, Meier-Hauff K, et al. F-FET PET for planning of thermotherapy using magnetic nanoparticles in recurrent glioblastoma. Int JHyperther. 2006;22:319-325. (Pubitemid 43878854)
211. Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun. 2008;29:193-207. (Pubitemid 351499295)
212. Zhou M, Zhang R, Huang M, et al. A chelator-free multifunctional [ Cu]Cu S nanoparticle platform for simultaneous micro-PET/CT im-aging and photothermal ablation therapy JACS. 2010;132:15351-15358.